Compare Adaptive Biotechnologies Corp (ADPT) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Rivian Automotive, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Rivian Automotive, Inc. trades at $16 (market cap $23.69B). The key difference: Rivian Automotive, Inc. is far larger — about 5.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | RIVN | |
|---|---|---|
Market Cap | $4.04B | $23.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $22.45 |
52-Week Low | $12.30 | $11.97 |
Enterprise Value | $4.10B | $23.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Rivian (RIVN) trades at $16.005, down 2.35% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company continues to report significant losses, with a net income margin of -54.95% for 2025, though revenue has grown to $5.39 billion. Recent news highlights the R2 vehicle launch and a partnership with Uber, providing potential growth catalysts amid ongoing cash burn concerns.
The outlook remains speculative; RIVN offers high growth potential through new vehicle ramps and software margins, but substantial execution risks and negative cash flow pose threats to near-term stability. Analyst consensus is cautiously optimistic with a $18.70 price target, yet the stock's path depends heavily on achieving profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
